Mitotech Sa News Today

Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech

HONG KONG, Oct 13, 2022 - (ACN Newswire) - Essex Bio-Technology Limited (the "Company", together with its subsidiaries, the "Group") wishes to announce that Essex Bio-Investment Limited ("Essex Bio-Investment")

HONG KONG, Oct 13, 2022 - (ACN Newswire) - Essex Bio-Technology Limited (the "Company", together with its subsidiaries, the "Group") wishes to announce that Essex Bio-Investment Limited ("Essex Bio-Investment"), a wholly-owned subsidiary of the Group has on 13 October 2022 successfully secured (i) a patent and know-how licence agreement; and (ii) a patent assignment deed (together as the "Agreements") in...

Achieves an increase of 58% in Profit-After-Tax to HK$346.0 million and Turnover Growth of 67.4% to HK$1,637.7 millionHONG KONG, Mar 22, 2022 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the

LUXEMBOURG, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Mitotech S.A, a Luxembourg-based clinical-stage biotechnology company, announced that its Chief Scientific...

The US Orphan Drug Designation would provide seven-year market exclusivity if Visomitin was approved for use in LHON....